查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954197

再生醫學創新市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、材料類型、設備、製程、最終用戶分類

Regenerative Medicine Innovations Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Material Type, Device, Process, End User
出版日期: | 出版商: Global Insight Services | 英文 306 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

再生醫學創新市場預計將從2024年的96億美元成長到2034年的568億美元，複合年成長率約為21.5%。再生醫學創新市場涵蓋旨在修復、替換或再生人體細胞、組織和器官以恢復正常功能的先進治療方法和技術。該市場包括幹細胞療法、組織工程和基因編輯，其成長動力主要來自慢性疾病的增加和人口老化。創新重點在於提高治療效果和可近性，而對研發的大量投資正在推動市場成長。

再生醫學創新市場正蓬勃發展，這主要得益於幹細胞研究和組織工程領域的進步。其中，幹細胞療法細分市場成長最為迅猛，這主要得益於慢性疾病細胞療法的突破性進展。組織工程緊隨其後，器官再生和生物材料應用領域發展勢頭強勁。基因療法雖然仍處於起步階段，但已發展成為第二大細分市場，展現出巨大的潛力，尤其是在治療遺傳性疾病方面。生物材料在再生醫學領域的應用日益廣泛，這反映了它們在支架構建和組織修復中發揮的關鍵作用。 CRISPR和3D生物列印等尖端技術的整合進一步推動了市場發展，因為這些創新提高了再生醫學的精準性和療效。生物技術公司與研究機構之間的合作正在加速產品開發和臨床試驗。監管政策的完善也為市場成長提供了支持，為再生醫學的商業化鋪平了道路。因此，預計再生醫學市場將強勁成長，為相關人員創造盈利的機會。

市場區隔
類型 細胞療法、基因療法、組織工程、幹細胞療法
產品 支架、生物材料、生物反應器、細胞培養系統
服務 法規諮詢、生產服務、臨床試驗服務
科技 CRISPR、CAR-T、3D生物列印、奈米技術
應用領域 整形外科和肌肉骨骼系統、循環系統系統、腫瘤科、皮膚科、神經科、眼科、糖尿病科
材料類型 天然聚合物、合成聚合物、水凝膠
裝置 植入式、穿戴式和診斷設備
過程 體內、體外
最終用戶 醫院、診所、研究機構、生技公司

再生醫學創新市場呈現動態的市場佔有率分佈格局，既有領導企業，也新興企業不斷取得顯著進展。定價策略競爭激烈，既反映了產品創新，也反映了提高可及性、降低成本的需求。近期產品推出主要集中於先進治療方法和個人化藥物，旨在滿足未被滿足的醫療需求，並激發市場興趣。這些趨勢支撐著強大的創新產品線，正在改變治療格局。再生醫學領域的競爭異常激烈，主要參與者正大力投資研發以維持競爭優勢。法規結構，尤其是在北美和歐洲，制定了嚴格的標準，影響產品核可和市場准入，對塑造市場動態至關重要。市場正經歷旨在加速創新和拓展市場的策略聯盟與合作激增。隨著監管機構根據新型治療方法不斷調整監管策略，預計在技術進步和醫療保健需求成長的推動下，市場將迎來顯著成長。

主要趨勢和促進因素：

再生醫學創新市場正經歷強勁成長，這主要得益於幹細胞研究和組織工程領域的進步。關鍵趨勢包括將人工智慧 (AI) 和機器學習融入再生醫學，以提高治療的精準度和療效。 3D 生物列印技術的興起正在革新複雜組織結構的建構方式，為個人化醫療提供了前所未有的機會。推動該市場發展的因素包括全球人口老化和慢性病日益增多，這些都需要創新的治療方案。監管支持和有利的報銷政策也在市場擴張中發揮關鍵作用。此外，公營和私營部門不斷增加的投資正在加速研發進程。新興市場醫療基礎設施的快速發展蘊藏著許多機會。專注於擴充性、具成本效益再生醫學解決方案的公司將佔據有利地位，從而獲得可觀的市場佔有率。同時，人們也越來越重視生物來源材料的永續和符合倫理的採購，這與全球環境責任的趨勢相符。在這些不斷發展的趨勢中，再生醫學創新市場預計將繼續成長，這得益於技術突破和對先進治療方法的強勁需求。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 細胞療法
    • 基因治療
    • 組織工程
    • 幹細胞療法
  • 市場規模及預測：依產品分類
    • 鷹架
    • 生物材料
    • 生物反應器
    • 細胞培養系統
  • 市場規模及預測：依服務分類
    • 監理諮詢
    • 製造服務
    • 臨床試驗服務
  • 市場規模及預測：依技術分類
    • CRISPR
    • CAR-T
    • 3D生物列印
    • 奈米科技
  • 市場規模及預測：依應用領域分類
    • 整形外科和肌肉骨骼
    • 心血管系統
    • 腫瘤學
    • 皮膚科
    • 神經病學
    • 眼科
    • 糖尿病
  • 市場規模及預測：依材料類型分類
    • 天然聚合物
    • 合成聚合物
    • 水凝膠
  • 市場規模及預測：依設備分類
    • 植入式裝置
    • 穿戴式裝置
    • 診斷設備
  • 市場規模及預測：依製程分類
    • In vivo
    • Ex Vivo
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 醫療設施
    • 研究所
    • 生技公司

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Mesoblast Limited
  • Athersys Inc
  • Pluristem Therapeutics Inc
  • Organogenesis Holdings Inc
  • Vericel Corporation
  • Sangamo Therapeutics Inc
  • Fate Therapeutics Inc
  • Cellectis SA
  • Cytori Therapeutics Inc
  • Tissue Gene Inc
  • Regenexx
  • Re Neuron Group plc
  • Bio Time Inc
  • Osiris Therapeutics Inc
  • Kiadis Pharma
  • Gamida Cell Ltd
  • Orgenesis Inc
  • Lineage Cell Therapeutics Inc
  • Cellular Biomedicine Group Inc
  • Blue Rock Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS32752

Regenerative Medicine Innovations Market is anticipated to expand from $9.6 billion in 2024 to $56.8 billion by 2034, growing at a CAGR of approximately 21.5%. The Regenerative Medicine Innovations Market encompasses advanced therapies and technologies aimed at repairing, replacing, or regenerating human cells, tissues, and organs to restore normal function. This market includes stem cell therapy, tissue engineering, and gene editing, driven by the rising prevalence of chronic diseases and an aging population. Innovations focus on enhancing treatment efficacy and accessibility, with significant investment in research and development fueling growth.

The Regenerative Medicine Innovations Market is flourishing, propelled by advancements in stem cell research and tissue engineering. The stem cell therapy segment emerges as the top performer, driven by breakthroughs in cellular therapies for chronic diseases. Tissue engineering follows closely, with applications in organ regeneration and biomaterials gaining momentum. Gene therapy, while still developing, shows promise as the second-highest performing sub-segment, particularly in addressing genetic disorders. The integration of biomaterials in regenerative applications is expanding, reflecting their critical role in scaffolding and tissue repair. The market is further invigorated by the convergence of cutting-edge technologies such as CRISPR and 3D bioprinting. These innovations are enhancing precision and efficacy in regenerative treatments. Collaborations between biotech firms and research institutions are accelerating product development and clinical trials. Regulatory advancements are also supporting market growth, providing a clearer pathway for the commercialization of regenerative therapies. Consequently, the market is poised for robust expansion, offering lucrative opportunities for stakeholders.

Market Segmentation
TypeCell Therapy, Gene Therapy, Tissue Engineering, Stem Cell Therapy
ProductScaffolds, Biomaterials, Bioreactors, Cell Culture Systems
ServicesRegulatory Consulting, Manufacturing Services, Clinical Trial Services
TechnologyCRISPR, CAR-T, 3D Bioprinting, Nanotechnology
ApplicationOrthopedic & Musculoskeletal, Cardiovascular, Oncology, Dermatology, Neurology, Ophthalmology, Diabetes
Material TypeNatural Polymers, Synthetic Polymers, Hydrogels
DeviceImplantable Devices, Wearable Devices, Diagnostic Devices
ProcessIn Vivo, Ex Vivo
End UserHospitals, Clinics, Research Institutes, Biotech Companies

The Regenerative Medicine Innovations Market is characterized by dynamic market share distribution, with emerging companies making significant inroads alongside established leaders. Pricing strategies are competitive, reflecting both the innovative nature of the products and the need for affordability to enhance accessibility. Recent product launches have emphasized advanced therapies and personalized medicine, catering to unmet medical needs and driving market interest. These developments underscore a robust pipeline of innovations poised to transform therapeutic landscapes. Competition in the regenerative medicine sector is intense, with key players investing heavily in research and development to maintain competitive advantage. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics, setting stringent standards that influence product approval and market entry. The market is witnessing a surge in strategic partnerships and collaborations, aimed at accelerating innovation and expanding market reach. As regulatory bodies evolve to accommodate novel therapies, the market is expected to experience significant growth, driven by technological advancements and increasing healthcare demands.

Geographical Overview:

The regenerative medicine innovations market is witnessing remarkable growth across various regions, each showcasing unique opportunities. North America leads the charge due to robust research infrastructure and substantial investments in biotechnological advancements. This region's focus on personalized medicine and stem cell research significantly propels market growth. Europe follows closely, with strong regulatory support and a thriving ecosystem for regenerative therapies. The region's commitment to innovation and collaboration fosters a conducive environment for market expansion. In the Asia Pacific, the market is expanding rapidly, driven by increasing government support and a growing emphasis on healthcare improvements. Countries like China and Japan are emerging as pivotal players, investing heavily in regenerative medicine research. Latin America and the Middle East & Africa are nascent markets with promising potential. Brazil and South Africa are recognizing the importance of regenerative medicine in addressing unmet medical needs, thereby paving the way for future growth and innovation.

The Regenerative Medicine Innovations Market is significantly influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea are strategically investing in domestic R&D to mitigate reliance on foreign biotechnologies, spurred by trade tensions and tariff implications. China is accelerating its focus on self-sufficiency in regenerative technologies, driven by export limitations and a strategic pivot to indigenous innovation. Taiwan, while a pivotal player in biotech manufacturing, navigates geopolitical challenges amid US-China tensions. Globally, the market is experiencing robust growth, propelled by advancements in gene therapies and stem cell research. By 2035, the market is poised for exponential expansion, contingent upon resilient supply chains and strategic international collaborations. Middle East conflicts exacerbate supply chain vulnerabilities and energy price volatility, impacting manufacturing costs and timelines.

Key Trends and Drivers:

The regenerative medicine innovations market is experiencing robust growth, propelled by advancements in stem cell research and tissue engineering. Key trends include the integration of artificial intelligence and machine learning in regenerative therapies, enhancing precision and outcomes. The rise of 3D bioprinting technology is revolutionizing the creation of complex tissue structures, offering unprecedented opportunities for personalized medicine. Drivers of this market include an aging global population and the increasing prevalence of chronic diseases, which necessitate innovative treatment solutions. Regulatory support and favorable reimbursement policies are also playing a crucial role in market expansion. Furthermore, the growing investment from both public and private sectors is accelerating research and development efforts. Opportunities abound in emerging markets where healthcare infrastructure is rapidly improving. Companies that focus on scalable and cost-effective regenerative solutions are well-positioned to capture significant market share. The emphasis on sustainable and ethical sourcing of biological materials is also gaining traction, aligning with global trends towards environmental responsibility. As these dynamics unfold, the regenerative medicine innovations market is set to thrive, driven by technological breakthroughs and a strong demand for advanced therapeutic options.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Material Type
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by End User

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Cell Therapy
    • 4.1.2 Gene Therapy
    • 4.1.3 Tissue Engineering
    • 4.1.4 Stem Cell Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Scaffolds
    • 4.2.2 Biomaterials
    • 4.2.3 Bioreactors
    • 4.2.4 Cell Culture Systems
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Regulatory Consulting
    • 4.3.2 Manufacturing Services
    • 4.3.3 Clinical Trial Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR
    • 4.4.2 CAR-T
    • 4.4.3 3D Bioprinting
    • 4.4.4 Nanotechnology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Orthopedic & Musculoskeletal
    • 4.5.2 Cardiovascular
    • 4.5.3 Oncology
    • 4.5.4 Dermatology
    • 4.5.5 Neurology
    • 4.5.6 Ophthalmology
    • 4.5.7 Diabetes
  • 4.6 Market Size & Forecast by Material Type (2020-2035)
    • 4.6.1 Natural Polymers
    • 4.6.2 Synthetic Polymers
    • 4.6.3 Hydrogels
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Implantable Devices
    • 4.7.2 Wearable Devices
    • 4.7.3 Diagnostic Devices
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 In Vivo
    • 4.8.2 Ex Vivo
  • 4.9 Market Size & Forecast by End User (2020-2035)
    • 4.9.1 Hospitals
    • 4.9.2 Clinics
    • 4.9.3 Research Institutes
    • 4.9.4 Biotech Companies

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Material Type
      • 5.2.1.7 Device
      • 5.2.1.8 Process
      • 5.2.1.9 End User
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Material Type
      • 5.2.2.7 Device
      • 5.2.2.8 Process
      • 5.2.2.9 End User
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Material Type
      • 5.2.3.7 Device
      • 5.2.3.8 Process
      • 5.2.3.9 End User
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Material Type
      • 5.3.1.7 Device
      • 5.3.1.8 Process
      • 5.3.1.9 End User
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Material Type
      • 5.3.2.7 Device
      • 5.3.2.8 Process
      • 5.3.2.9 End User
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Material Type
      • 5.3.3.7 Device
      • 5.3.3.8 Process
      • 5.3.3.9 End User
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Material Type
      • 5.4.1.7 Device
      • 5.4.1.8 Process
      • 5.4.1.9 End User
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Material Type
      • 5.4.2.7 Device
      • 5.4.2.8 Process
      • 5.4.2.9 End User
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Material Type
      • 5.4.3.7 Device
      • 5.4.3.8 Process
      • 5.4.3.9 End User
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Material Type
      • 5.4.4.7 Device
      • 5.4.4.8 Process
      • 5.4.4.9 End User
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Material Type
      • 5.4.5.7 Device
      • 5.4.5.8 Process
      • 5.4.5.9 End User
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Material Type
      • 5.4.6.7 Device
      • 5.4.6.8 Process
      • 5.4.6.9 End User
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Material Type
      • 5.4.7.7 Device
      • 5.4.7.8 Process
      • 5.4.7.9 End User
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Material Type
      • 5.5.1.7 Device
      • 5.5.1.8 Process
      • 5.5.1.9 End User
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Material Type
      • 5.5.2.7 Device
      • 5.5.2.8 Process
      • 5.5.2.9 End User
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Material Type
      • 5.5.3.7 Device
      • 5.5.3.8 Process
      • 5.5.3.9 End User
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Material Type
      • 5.5.4.7 Device
      • 5.5.4.8 Process
      • 5.5.4.9 End User
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Material Type
      • 5.5.5.7 Device
      • 5.5.5.8 Process
      • 5.5.5.9 End User
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Material Type
      • 5.5.6.7 Device
      • 5.5.6.8 Process
      • 5.5.6.9 End User
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Material Type
      • 5.6.1.7 Device
      • 5.6.1.8 Process
      • 5.6.1.9 End User
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Material Type
      • 5.6.2.7 Device
      • 5.6.2.8 Process
      • 5.6.2.9 End User
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Material Type
      • 5.6.3.7 Device
      • 5.6.3.8 Process
      • 5.6.3.9 End User
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Material Type
      • 5.6.4.7 Device
      • 5.6.4.8 Process
      • 5.6.4.9 End User
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Material Type
      • 5.6.5.7 Device
      • 5.6.5.8 Process
      • 5.6.5.9 End User

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Mesoblast Limited
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Athersys Inc
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Pluristem Therapeutics Inc
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Organogenesis Holdings Inc
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Vericel Corporation
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Sangamo Therapeutics Inc
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Fate Therapeutics Inc
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Cellectis SA
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Cytori Therapeutics Inc
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Tissue Gene Inc
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Regenexx
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Re Neuron Group plc
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Bio Time Inc
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Osiris Therapeutics Inc
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Kiadis Pharma
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Gamida Cell Ltd
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Orgenesis Inc
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Lineage Cell Therapeutics Inc
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Cellular Biomedicine Group Inc
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Blue Rock Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us